We are live on ! Find out more
CLCD

CoLucid Pharmaceuticals, Inc.
CLCD

Delisted

CLCD was delisted on the 28th of February, 2017.

Back to rankings

56 hedge funds and large institutions have $472M invested in CoLucid Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

925% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 4

921% more capital invested

Capital invested by funds: $46.3M → $472M (+$426M)

500% more funds holding in top 10

Funds holding in top 10: 1 → 6 (+5)

233% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 3

180% more funds holding

Funds holding: 20 → 56 (+36)

Holders
56
Holders Change
+36
Holders Change %
+180%
% of All Funds
1.49%
Holding in Top 10
6
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+500%
% of All Funds
0.16%
New
41
Increased
10
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$17.1M
2
BI
BVF Inc
California
+$11.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.6M
4
PA
Perceptive Advisors
New York
+$8.16M
5
GPP
Great Point Partners
Connecticut
+$5.91M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$1.48M
2
EAM
EverPoint Asset Management
Connecticut
-$650K
3
SG Americas Securities
SG Americas Securities
New York
-$464K
4
UOC
UBS O'Connor
Illinois
-$368K
5
MAM
MPM Asset Management
Massachusetts
-$178K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$120M +$1.48M +100,000 +3%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$94.9M +$17.1M +1,158,959 +87%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$29.9M +$10.6M +715,619 +1,056%
BI
4
BVF Inc
California
$29.1M +$11.3M +763,300 New
PA
5
Perceptive Advisors
New York
$21.1M +$8.16M +552,030 New
SFM
6
Sphera Funds Management
Israel
$15.3M -$1.48M -100,137 -20%
GPP
7
Great Point Partners
Connecticut
$15.3M +$5.91M +400,000 New
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$11.4M +$4.43M +300,000 New
AIC
9
AWM Investment Company
New York
$11M +$4.27M +288,919 New
EAM
10
EverPoint Asset Management
Connecticut
$10.9M -$650K -43,979 -13%
Vanguard Group
11
Vanguard Group
Pennsylvania
$9.86M +$2.69M +182,083 +239%
EI
12
EAM Investors
California
$9.18M +$3.56M +240,507 New
CIP
13
Chartwell Investment Partners
Pennsylvania
$8.66M +$3.36M +227,040 New
VC
14
Vivo Capital
California
$8.58M +$3.33M +225,000 New
Marshall Wace
15
Marshall Wace
United Kingdom
$6.85M +$2.65M +179,480 New
VMI
16
VHCP Management II
New York
$6.07M +$2.35M +159,110 New
KCM
17
Kingdon Capital Management
New York
$5.91M +$2.29M +154,963 New
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$4.1M +$1.59M +107,500 New
NC
19
Nexthera Capital
New York
$3.81M +$1.48M +100,000 New
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$3.54M +$1.37M +92,784 New
Renaissance Technologies
21
Renaissance Technologies
New York
$3.53M +$1.37M +92,600 New
BIT
22
BlackRock Institutional Trust
California
$3.42M +$1.33M +89,693 New
PC
23
PointState Capital
New York
$3.04M +$1.18M +79,700 New
JGC
24
J. Goldman & Co
New York
$2.98M +$1.16M +78,176 New
Citadel Advisors
25
Citadel Advisors
Florida
$2.96M +$1.15M +77,707 New
1
2 3

CLCD Hedge Fund Activity: Q3 2016 in Review

56 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q3 2016, worth a combined $472M — up 921% from $46.3M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new CLCD positions and 4 closed out — a net gain of 37 holders — while 10 added to existing stakes and 3 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $17.1M. The largest seller was Sphera Funds Management, cutting an estimated $1.48M.

  • 56 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q3 2016, up from 20 in Q2 2016.
  • Funds reported $472M of CoLucid Pharmaceuticals, Inc. stock for Q3 2016, up 921% quarter-over-quarter.
  • 41 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q3 2016 and 4 closed out, a net change of +37 holders.
  • The largest CoLucid Pharmaceuticals, Inc. buyer in Q3 2016 was T. Rowe Price Associates, an estimated $17.1M added.
  • The largest CoLucid Pharmaceuticals, Inc. seller in Q3 2016 was Sphera Funds Management, an estimated $1.48M sold.

Based on aggregated 13F filings for Q3 2016.